July 10, 2017 / 1:01 PM / a month ago

BRIEF-Exelixis, Bristol-Myers Squibb initiate phase 3 trial

July 10 (Reuters) - Bristol-myers Squibb Co:

* Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx, versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma

* Bristol-Myers Squibb Co - ‍exelixis, Bristol-Myers Squibb and Ipsen to co-fund trial​

* Bristol-Myers Squibb Co - ‍checkmate 9ER is an open-label, randomized, multi-national phase 3 trial that aims to enroll approximately 1,014 patients​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below